SCHEMBL633929

SCHEMBL633929

CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)N1CCCCCN1C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)C1(C)C

nearest known ligand 0.90

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.88
PGR P06401 1/20 0.88
HDAC1 Q13547 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025722 0.95 AR (0.98) ARPGRHDAC1
SCHEMBL630193 0.95 AR (0.80) ARPGRHDAC1
Ru-58841 SCHEMBL1461459 0.94 AR (1.00) ARPGRHDAC1
Ru-58841 SCHEMBL29372187 0.94 AR (1.00) ARPGRHDAC1
SCHEMBL7786228 0.94 AR (0.81) ARPGR
SCHEMBL4032680 0.94 PGR (0.81) ARPGR
SCHEMBL5579470 0.94 AR (0.81) ARPGR
SCHEMBL7781110 0.93 AR (0.80) ARPGR
SCHEMBL2694365 0.93 AR (0.94) ARPGR
SCHEMBL12843361 0.92 AR (0.79) ARPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2419422-B1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA SAS (FR) 2014-10-15 EP disclosed
US-8624037-B2 Imidazolidine-2,4-dione derivatives and use thereof as a medicament IPSEN PHARMA S.A.S. (FR) 2014-01-07 US disclosed
US-20120095068-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA S.A.S. (FR) 2012-04-19 US disclosed
EP-2419422-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA S.A.S. (FR) 2012-02-22 EP disclosed
WO-2010119194-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA S.A.S. (FR) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095068-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT MKI67, CCNI, CCNA1 AR 2479/4885PGR 658/4885HDAC1 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.